Nature biomedical engineering

Nature Biomedical Engineering (nature-biomedical-engineering)

Journal positioning

Nature Biomedical Engineering is the Nature Portfolio journal for engineering at the interface with biology and medicine: devices, diagnostics, therapeutics, biomaterials, and engineered systems whose advance carries significance for medicine or biology and plausible translational relevance. It selects, in the Nature style, for work that solves a real biomedical problem with rigorous, biologically or clinically meaningful validation — not a clever engineering demonstration with no health significance. The defining demand is that the engineering be motivated by, and validated against, a genuine medical or biological need; a proof-of-concept device with only benchtop data and no biological/clinical evidence is a poor fit. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official author guidelines. Before submitting, re-check the live Nature Biomedical Engineering submission guidelines on the Nature Portfolio site.

When to trigger

• The author names Nature Biomedical Engineering for a device, diagnostic, therapeutic, or biomaterial result and wants a fit/framing and significance check.
• An engineering result must be re-framed from a benchtop demonstration into a biomedical-significance and translational narrative with biological validation.
• The author is choosing between Nature Biomedical Engineering and biomaterials, nature-electronics, ieee-transactions-on-biomedical-engineering, or nature-communications.
• The author needs the journal's validation bar and its desk-reject heuristics.

Scope & topic fit

• Medical devices and engineered systems: implantable, wearable, and point-of-care technologies validated against a clinical or biological endpoint.
• Diagnostics and biosensing: assays, imaging, and sensor platforms with demonstrated sensitivity/specificity on biologically or clinically relevant samples.
• Therapeutics and delivery: engineered drug/gene/cell-delivery systems and device-enabled therapies with mechanism and efficacy evidence in relevant models.
• Biomaterials and tissue engineering when the advance is engineering-driven and tied to a biomedical function and validation, not just material characterization.
• Bioelectronics, neural interfaces, and organ-on-chip / engineered tissue systems with measured biological performance.
• Computational and AI methods for biomedicine when validated on clinically or biologically meaningful data with appropriate endpoints.

Method & evidence bar

• The contribution must carry an explicit biomedical-significance argument: the unmet need, the engineered solution, and why it matters for medicine or biology.
• Validation must match the claim's level: cell/tissue, animal-model, or human/clinical evidence with appropriate controls, endpoints, and statistics — benchtop performance alone is insufficient for a biomedical claim.
• Performance must be benchmarked against the relevant clinical or technological state of the art and reported under stated, comparable conditions.
• Biological and animal studies require proper experimental design (randomization, blinding where applicable, adequate N, ethics approval) and honest reporting of limitations.
• Translational claims must be calibrated to the evidence: clearly distinguish proof-of-concept from validated performance, and state remaining barriers.
• Reproducibility and reporting follow Nature-Portfolio expectations, including the reporting summary and relevant reporting guidelines for biomedical studies.

Structure & house style

• Nature-Portfolio article structure with a significance-forward abstract and introduction; re-check current article types and length/format on the live guide.
• The introduction frames the clinical/biological problem and the engineering rationale before technical development, in accessible language.
• Main display items are curated and load-bearing: device/assay performance with statistics, in-vitro/in-vivo results with controls, and clear schematics of the system and its intended use.
• Methods and extended/supplementary material carry full fabrication, assay, model, and statistical detail; the main narrative must stand on the headline figures.
• Ethics, biosafety, and trial-registration statements must be present where applicable.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the Nature-Portfolio anchors, then cite the current Nature Biomedical Engineering guidelines page you checked.
• Search the live site for "Nature Biomedical Engineering submission guidelines" and follow the current Nature-Portfolio submission system.
• Re-check article types, length/format expectations, and the abstract requirements.
• Confirm ethics approval, animal-use (e.g., ARRIVE), clinical-trial registration, and relevant reporting-guideline requirements for biomedical studies.
• Confirm data-availability, code-availability, and reporting-summary requirements of Nature Portfolio.
• Re-check open-access options, ORCID, competing-interests, funding, author-contribution, and AI-use disclosure requirements.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• The abstract/introduction states the unmet biomedical need and the translational significance in Nature style.
• Validation matches the claim level (cell / animal / human) with proper controls, endpoints, and statistics.
• Performance is benchmarked against the relevant clinical or technological state of the art.
• Animal/clinical studies report design (N, randomization/blinding), ethics approval, and limitations honestly.
• Translational claims are calibrated to the evidence, distinguishing proof-of-concept from validated performance.
• Data/code availability, reporting summary, and biomedical reporting guidelines are satisfied.

Common desk-reject triggers

• An engineering demonstration with no biomedical significance or no biological/clinical validation.
• Benchtop-only performance presented as a biomedical claim without in-vitro/in-vivo evidence.
• Overstated translational claims unsupported by the level of validation provided.
• Animal or clinical data with inadequate design, missing controls, or absent ethics approval.
• Performance not benchmarked against the relevant clinical or technological standard of care.
• A materials or device paper better suited to a materials or specialty engineering venue.

Re-routing decision

• Biomaterials advance centered on material design with biological evaluation → biomaterials.
• Bioelectronic/device physics advance without strong biomedical validation → nature-electronics.
• Specialty biomedical-engineering methods/instrumentation result → ieee-transactions-on-biomedical-engineering.
• Broad cross-disciplinary significance beyond biomedicine → nature-communications / science-advances.
• Mechanistic biology or therapeutic biology as the core → a dedicated biomedical/biology Nature-Portfolio venue.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Nature Biomedical Engineering
[Topic tags] <2–3 closest biomedical-engineering subtopics>
[Significance statement] <the unmet need + translational claim in one line>
[Validation level] benchtop / in-vitro / in-vivo / human-clinical
[Method/evidence] <does validation + benchmarking clear the biomedical significance + rigor bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / ethics & reporting guidelines / data & code / reporting summary / OA / disclosures>
[Re-route suggestion] <if no biomedical validation or better framed elsewhere, a matched venue>